9. January 2015

FDA Approves Roche's Blood Screening Assay for Simultaneous Detection and Identification of Three Major Viral Targets

Roche announced today that the FDA has approved the cobas® TaqScreen MPX Test, v2.0 for use in the detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma.


Learn about testing for EGFR in non-small cell lung cancer
What's New

13. November 2015

Roche receives FDA approval for cobas® EGFR Mutation Test v2 as a companion diagnostic for non-small cell lung cancer therapies

Next-generation test using tissue samples is approved for use as a companion diagnostic with AstraZeneca’s new therapy, TAGRISSO™.


3. November 2015

Roche expands cobas 4800 System menu with HIV-1, HCV and HCV Genotyping Tests

Roche announced today the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark1.


19. October 2015

Roche receives FDA approval for viral load tests and cobas 6800/8800 Systems

Roche announced that it has received FDA approval for the cobas® HBV and cobas® HCV viral load tests, the first assays approved by the United States Food and Drug Administration for use on the cobas® 6800 and cobas® 8800 Systems.


28. September 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

New test is the first to be validated for use of either sample type in a single test.


 Diagnostic and Blood Screening Tests


Roche Molecular Diagnostics (RMD) offers a uniquely broad range of diagnostic and blood screening assays based on the company's Nobel prize-winning PCR technologies.


RMD's tests and automated platforms are focused in the areas of virology, blood screening, HPV, genomics and oncology, microbiology and sexually transmitted infections. > more


Contact your local sales representative for detailed information, questions and ordering.



 Browse Our Products

 Related Links